China’s Kexing Pharmaceutical (SHA: 688136) has secured a global commercialization licensing agreement with Qingfeng Pharmaceutical Group for the latter’s generic version of olaparib. Under this deal, Kexing will obtain commercial rights for the product across an initial batch of 10 international markets. Meanwhile, Qingfeng’s generic formulation is currently awaiting regulatory approval in China.
Olaparib, a PARP inhibitor originally developed by AstraZeneca and marketed as Lynparza, received its first US approval in 2014 for the treatment of advanced ovarian cancer with BRCA mutations. It has since gained approval for use in various other cancers, including breast, pancreatic, and prostate cancers. The original drug was granted approval in China in August 2018.- Flcube.com
